ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0982

Systemic Autoimmune Rheumatic Diseases (SARD) in the Agricultural Health Study Cohort: Rates of Rheumatoid Arthritis (RA) and Other SARD Among Medicare-linked Participants

Christine Parks1, Karen Costenbader2, Laura Beane Freeman3, Jonathan Hofmann3 and Dale Sandler4, 1Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 4Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, NC

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, Cohort Study, Environmental factors, Epidemiology, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (0965–0992) Epidemiology & Public Health Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Some systemic autoimmune rheumatic diseases (SARD), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), have been associated with farming, specific pesticides, and other occupational exposures in the Agricultural Health Study (AHS), a prospective cohort of ~89,000 licensed pesticide applicators and spouses in North Carolina and Iowa enrolled in 1993-1997. We previously identified incident RA based on self-report confirmed by DMARD use and case validation, e.g., 220 cases (0.8%) among 26,354 male private pesticide applicators with available follow-up data through 2010. However, incomplete cohort follow-up limits the assessment of disease rates, and many rarer SARD were not included on questionnaires. Thus, we used cohort-linked Medicare claims data to enhance case ascertainment for future analyses of agricultural exposures and risk of SARD.

Methods: The AHS cohort includes licensed pesticide applicators (N=52,394 private and 4,916 commercial, 97% male) and spouses (32,345, 99% female). We assessed SARD prevalence based on Medicare claims data from 1999-2016 in 35,506 participants (21,554 male) who enrolled in Medicare at ages ≥65 years with ≥1 year of Fee for Service coverage (FFS; Parts A and B, but not Part C). We sought to identify cases of 15 SARD using ICD codes, requiring ≥2 disease-specific claims ≥30 days apart. In a subset of 33,398 (20,132 male) with a 24-month clean period (i.e., continuous FFS with no SARD-specific claims), we identified incident cases and calculated age- and sex-standardized incidence rates.

Results: Overall, we identified 1987 SARD cases (5.33%), including 892 (4.15%) among males (Table 1). The top 5 diagnoses were rheumatoid arthritis (1,032; 2.90%), polymyalgia rheumatica (PMR, N=639; 1.80%), sicca syndrome (SS, 128; 0.36%), SLE (111; 0.31%), and giant cell arteritis (GCA; 108; 0.30%). Among males, prevalence was slightly lower for RA (480; 2.23%), PMR (325; 1.51%), and GCA (45; 0.21%), and substantially lower for SS (27; 0.12%) and SLE (35; 0.16%). A total of 1305 (3.91%) met the criteria for incident SARD, including 636 (3.13%) male cases, with 287 (1.43%) incident RA, 273 (1.36%) PMR, and the remaining rarer SARD (0-0.20%; Table 2).

Conclusion: In this agricultural cohort, about 1 in 20 older individuals was diagnosed with an SARD based on Medicare claims. Incidence of Medicare-based RA in males was greater than we previously identified by questionnaire. These data will facilitate comparisons of SARD in the AHS with published rates in the Medicare population and will enhance research on the role of pesticides and other exposures in the development of SARD in older AHS participants.

Supporting image 1

Table 1 – Prevalence of Systemic Autoimmune Rheumatic Diseases in the Agricultural Health Study

Supporting image 2

Table 1 – Incidence of Systemic Autoimmune Rheumatic Diseases in the Agricultural Health Study


Disclosures: C. Parks: None; K. Costenbader: Amgen, 2, 5, AstraZeneca, 5, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Eli Lilly, 2, Exagen Diagnostics, 5, Gilead, 5, GlaxoSmithKlein(GSK), 2, 5, Janssen, 2, 5; L. Beane Freeman: None; J. Hofmann: None; D. Sandler: None.

To cite this abstract in AMA style:

Parks C, Costenbader K, Beane Freeman L, Hofmann J, Sandler D. Systemic Autoimmune Rheumatic Diseases (SARD) in the Agricultural Health Study Cohort: Rates of Rheumatoid Arthritis (RA) and Other SARD Among Medicare-linked Participants [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/systemic-autoimmune-rheumatic-diseases-sard-in-the-agricultural-health-study-cohort-rates-of-rheumatoid-arthritis-ra-and-other-sard-among-medicare-linked-participants/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-autoimmune-rheumatic-diseases-sard-in-the-agricultural-health-study-cohort-rates-of-rheumatoid-arthritis-ra-and-other-sard-among-medicare-linked-participants/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology